Eris Lifesciences Limited on Tuesday announced that one of its sterile injectable manufacturing facilities in Ahmedabad has received approval from ANVISA, Brazil’s national health regulatory agency. This milestone comes shortly after the company’s oral dose manufacturing unit also received ANVISA’s clearance earlier this year.
The approved facility is part of Swiss Parenterals, which Eris acquired in 2024. The inspection for both injectable plants was conducted in April 2025, and the company expects approval for the second facility soon. Both facilities are already EU-GMP and PIC/s approved, catering to several Latin American markets such as Mexico, Chile, Argentina, and Peru.
According to the company, the ANVISA nod will enable the launch of injectable products in Brazil, strengthening Eris’ coverage of the Latin American pharmaceutical market. Commenting on the development, CMD Amit Bakshi said, “This approval is yet another endorsement of our operating and quality standards in life-saving dosage forms. It brings us closer to our strategic transformation into a company with increasing focus and leadership in complex injectables and biotechnology.”
Eris Lifesciences, founded in 2007, is among the youngest in India’s top 20 pharma firms, with revenues crossing ₹2,894 crore in FY25. The company has diversified its presence across diabetes, cardiovascular, dermatology, oncology, women’s health, and critical care, supported by six manufacturing facilities and a network of over 5,00,000 retail pharmacies nationwide.